|Bid||21.34 x 1100|
|Ask||21.51 x 1200|
|Day's Range||21.24 - 21.54|
|52 Week Range||14.27 - 22.83|
|PE Ratio (TTM)||44.91|
|Dividend & Yield||0.33 (1.52%)|
|1y Target Est||22.63|
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Grifols SA Here are 5 ETFs with the largest exposure to GRFS-US. Comparing the performance and risk of Grifols SA with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Grifols SA reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 1,264.20 million, Net Earnings of USD 160.84 million. Gross margins widened from 45.26% to 47.95% compared to the same period last year, operating (EBITDA) margins now 29.92% from 27.31%. Change in operating cash ... Read more (Read more...)
The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.
Phocus Rx® is Live with Bidirectional Interfaces with Three of the Top Five Hospital Information Systems in the US BARCELONA, Spain , Aug. 22, 2017 /PRNewswire/ -- Phocus Rx ® enhances safety and improves ...
- American Red Cross is testing selected donations collected in areas of the U.S. that are endemic for the tick known to carry the Babesia parasite - The data collected will be used in the submission process ...
BARCELONA, Spain, June 22, 2017 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines, and a leader in the development of innovative diagnostic solutions, is expanding its Texas-based Clinical Diagnostics Laboratory menu by launching therapeutic drug monitoring testing services. As the standard of care changes towards individualized patient care in diseases such as inflammatory bowel diseases, the clinicians' demand for monitoring biologic drugs is growing.
BARCELONA, June 12, 2017 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, and Beckman Coulter Inc., a leading provider of innovative, efficient and reliable diagnostics solutions, have entered into an exclusive, long-term agreement for the global distribution of Grifols' hemostasis instruments, reagents and consumables. "Grifols continues to execute its strategy in growing the Specialty Diagnostics line. "Beckman Coulter's long-term partnership with Grifols expands our extensive diagnostic product offering and further supports our position as a partner of choice with hospitals and clinical laboratories across the world," stated Arnd Kaldowski, President of Beckman Coulter Diagnostics.
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Grifols SA with the following peers – Baxter International Inc., China Biologic Products, Inc., Amgen Inc., China Cord Blood Corporation, Kimberly-Clark Corporation, Johnson & Johnson, Cord Blood America, Inc., Aradigm Corporation and Mylan N.V. (BAX-US, CBPO-US, AMGN-US, CO-US, KMB-US, JNJ-US, CBAI-US, ARDM-US and MYL-US). Dividend ... Read more (Read more...)
Hologic crushed Wall Street's fiscal second-quarter revenue and profit expectations late Wednesday, led by double-digit growth.
BARCELONA, Spain, May 9, 2017 /PRNewswire/ -- Test is designed to detect the presence in whole blood, of the four clinically relevant species of Babesia ( B. microti, B. duncani, B. divergens, and B. ...
VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of 13 cents
GlaxoSmithKline plc's (GSK) first quarter results came roughly in line with expectations. Glaxo reported first-quarter 2017 core earnings of 62 cents per American Depositary Share (ADS), in line with the Zacks Consensus Estimate.
EMERYVILLE, Calif., April 24, 2017 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company with a history of more than 75 years of improving people's health and well-being and a leader in the development of innovative diagnostic solutions, announces that it has restated its 2005 agreement with OraSure Technologies ("OraSure"), a leader in point-of-care diagnostic tests. The test is FDA approved for qualitatively detecting hepatitis C virus antibodies in whole blood obtained through the use of a fingerstick or venipuncture.
The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.
BARCELONA, Spain, April 17, 2017 /PRNewswire/ -- Today, Grifols, S.A. (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) announced that it will donate a minimum of 140 million international units (IU) of blood clotting factor medicines (Factor VIII) to the World Federation of Hemophilia (WFH) Humanitarian Aid Program over the next five (5) years. This announcement is a continuation of the Company's three-year commitment from 2014, bringing the total humanitarian aid commitment to more than 200M IU of Factor VIII over eight years.